Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users

Maturitas

Volumn 27, Issue 2, 1997, Pages 133-143

  Hänggi, Willy ^a,b   Bersinger, Niklaus ^a   Altermatt, Hans Jörg ^a   Birkhäuser, Martin Hans ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Universitats Frauenklinik   (Switzerland)

Author keywords

Dydrogesterone; Endometrium; Estradiol; Hormone Replacement Therapy; Tibolone; Ultrasonography

Indexed keywords

DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; ENDOMETRIUM BIOPSY; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; TRANSVAGINAL ECHOGRAPHY;

EID: 0343924650     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00037-6     Document Type: Article

References (47)

1. te Velde ER, van Leusden HAIM. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994;343:654-8.
2. Fantl JA, Cardozo L, McClish DK. The Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incontinence in postmenopausal women: A meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol 1994;83:12-8.
3. Compston JE. Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects. Reprod Med Rev 1994;3:209-24.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
6. The Writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
7. Gambrell RD. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-68.
8. Barentsen R, Groeneveld FPMJ, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993;51:203-7.
9. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1995;20:91-9.
10. Padwick ML, Pryse-Davies J, Whitehead MI. A simple method for determining the optimal dose of progestin in postmenopausal women receiving oestrogens. N Engl J Med 1986;315:930-4.
11. Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333-8.
12. Feldman S, Berkowitz RS, Tosteson ANA. Cost-effectiveness of strategies to evaluate postmenopausal bleeding. Obstet Gynecol 1993;81:968-75.
13. Smith JJ, Schulman H. Current dilatation and curettage practice: A need for revision. Obstet Gynecol 1985;65:516-8.
14. Osmers Völksen M, Schauer A. Vaginosonography for early detection of endometrial carcinoma? Lancet 1990;335:1569-71.
15. Klug PW, Leitner G. Die Gegenüberstellung vaginalsonographischer und histologischer Befunde am Endometrium. Geburtshilfe Frauenheilkd 1989;49:797-802.
16. Sladkevicius P, Valentin L, Marsál K. Endometrial thickness and Doppler velocimetry of uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study. Am J Obstet Gynecol 1994;171:722-8.
17. Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990;163:119-23.
18. Nasri MN, Shepherd JH, Setchell ME, Lowe DG, Chard T. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynecol 1991;98:470-5.
19. Hänggi W, Riesen W, Birkhäuser MH. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993;31:645-50.
20. Hänggi W, Linder HR, Birkhäuser MH, Schneider H. Microscopic findings of the nail-fold capillaries - dependence on menopausal status and hormone replacement therapy. Maturitas 1995a;22:37-46.
21. Gordon AN, Fleischer AC, Reed GW. Depth of myometrial invasion in endometrial cancer: preoperative assessment by transvaginal ultrasonography. Gynecol Oncol 1990;39:321-7.
22. Gambrell RD, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-8.
23. Cornier E. The Pipelle: a disposable device for endometrial biopsy. Am J Obstet Gynecol 1984;148:109-10.
24. Wikland M, Granberg S, Karlsson B. Replacing diagnostic curettage by vaginal ultrasound. Eur J Obstet Gynecol Reprod Biol 1993;49:35-8.
25. Varner RE, Sparks JM, Cameron CD, Roberts LL, Soong S-J. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991;78:195-9.
26. Meuwissen JHJM, van Langen H, Moret E, Navarro-Morquecho I. Monitoring of oestrogen replacement therapy by vaginosonography of the endometrium. Maturitas 1992;15:33-7.
27. Castelo-Branco C, Puerto B, Durán M, Gratacós E, Torné A, Fortuny A, Vanrell JA. Transvaginal sonography of the endometrium in postmenopausal women: monitoring the effect of hormone replacement therapy. Maturitas 1994;19:59-65.
28. Hänggi W, Brandenberger AW, Ammann M, Dietz TU, Herrmann U. Diagnostik maligner Uterus-Tumoren durch die transvaginale Sonographie. Ultraschall Med 1995b;16:2-7.
29. Degenhardt F, Böhmer S, Frisch K, Schneider J. Vaginosonographische Endometriumkontrolle in der Menopause. Ultraschall Med 1991;12:119-23.
30. Granberg S, Wikland M, Karlsson B, Norström A, Friberg L-G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47-52.
31. Cacciatore B, Ramsay T, Lehtovirta P, Ylöstalo P. Transvaginal sonography and hysteroscopy in postmenopausal bleeding. Acta Obstet Gynecol Scand 1994;73:413-6.
32. Bakos O, Smith P, Heimer G. Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women. Maturitas 1995;20:181-9.
33. Karlsson B, Granberg S, Wikland M, Ylöstalo P, Torvid K, Marsal K, Valentin L. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488-94.
34. Eddowes HA, Read MD, Codling BW. Pipelle: a more acceptable technique for outpatient endometrial biopsy. Br J Obstet Gynaecol 1990;97:961-2.
35. Fothergill DJ, Brown VA, Hill AS. Histological sampling of the endometrium - a comparison between formal curettage and the Pipelle sampler. Br J Obstet Gynaecol 1992;99:779-80.
36. Kaunitz AM, Masciello A, Ostrowski M, Rovira EZ. Comparison of endometrial biopsy with the endometrial Pipelle and Vabra aspirator. J Reprod Med 1988;33:427-31.
37. Siddle NC, Jesinger DK, Whitehead MI, Turner P, Lewis B, Prescott P. Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990a;97:1093-1100.
38. Vermorken AJM, Sultan C, Goos CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1987;1:167-72.
39. Visser J de, Coert A, Feenstra H, Vies J van der. Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Arzneimittelforschung 1984;34:1010-7.
40. Ross LA, Alder EM. Tibolone and climacteric symptoms. Maturitas 1995;21:127-36.
41. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314-9.
42. Genazzani AR, Benedek Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD 14 and the endometrium. Maturitas 1991;13:243-51.
43. van der Mooren MJ, Hanselaar AGJM, Borm GF, Rolland R. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas 1995;20:175-80.
44. Burch DJ, Spowart KJM, Jesinger DK, Randall S, Smith SK. A dose-ranging study on the use of cyclical dydrogesterone with continuous 17β oestradiol Br J Obstet Gynaecol 1995;102:243-8.
45. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3β-hydroxysteroid dehydrogenase/ isomerase can locally reduce intrinsic estrogenic/ progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 1993;45:345-51.
46. Pirhonen JP, Vuento MH, Mäkinen JI, Salmi TA. Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am J Obstet Gynecol 1993;168:620-3.
47. Zalud I, Conway C, Schulman H, Trinca D. Endometrial and myometrial thickness and uterine blood flow in postmenopausal women: the influence of replacement therapy and age. J Ultrasound Med 1993;12:737-41.